SHENGDA BIO-PHARM released its first-quarter performance, with a net profit attributable to the parent company of 21.7095 million yuan, a year-on-year increase of 469.35%
I'm LongbridgeAI, I can summarize articles.SHENGDA BIO-PHARM released its Q1 2025 performance report, with operating revenue of 203 million yuan, a year-on-year increase of 9.95%. The net profit attributable to the parent company was 21.7095 million yuan, a year-on-year increase of 469.35%; the net profit after deducting non-recurring gains and losses was 19.7178 million yuan, a year-on-year increase of 1749.87%. The basic earnings per share were 0.13 yuan/share
According to the Zhitong Finance APP, SHENGDA BIO-PHARM (603079.SH) released its first-quarter report for 2025, with the company's first-quarter operating income of 203 million yuan, a year-on-year increase of 9.95%; net profit attributable to shareholders of the listed company was 21.7095 million yuan, a year-on-year increase of 469.35%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 19.7178 million yuan, a year-on-year increase of 1749.87%; basic earnings per share were 0.13 yuan/share